Ozanimod's effect on the progression of disability is unclear and cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources, according to final guidance.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us